CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel(†)

BACKGROUND: Paclitaxel-induced neuropathy is an adverse event that often leads to therapeutic disruption and patient discomfort. We attempted to replicate a previously reported association between increased neuropathy risk and CYP2C8*3 genotype. PATIENTS AND METHODS: Demographic, treatment, and toxi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Hertz, D. L., Roy, S., Motsinger-Reif, A. A., Drobish, A., Clark, L. S., McLeod, H. L., Carey, L. A., Dees, E. C.
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2013
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3660078/
https://ncbi.nlm.nih.gov/pubmed/23413280
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdt018
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados